DJIA 15,973.84 313.66 2.00%
NASDAQ 4,337.51 70.68 1.66%
S&P 500 1,864.78 35.70 1.95%
market minute promo

Novartis (NYSE: NVS)

72.70 0.50 (0.69%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

NVS $72.70 0.69%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $72.35
Previous Close $72.20
Daily Range $71.83 - $72.76
52-Week Range $71.55 - $106.84
Market Cap $174.2B
P/E Ratio 19.51
Dividend (Yield) $2.67 (3.2%)
Ex-Dividend Date
Dividend Pay Date
02/24/16
01/01/70
Volume 2,123,249
Average Daily Volume 2,513,901
Current FY EPS $5.19

Sector

Healthcare

Industry

Drug Makers

Novartis (NVS) Description

Operates in the business of patent-protected and generic pharmaceuticals as well as consumer health products. Website: http://www.novartis.com/

News & Commentary Rss Feed

Will 2016 Be Novartis' Worst Year Yet?

WIth its top seller facing increased generic competition, this could be a very bad year, indeed.

Novartis Filing for Neulasta Biosimilar Accepted in the EU

Incyte (INCY) Beats on Q4 Earnings and Revenue Estimates

VEU, NSRGY, NVS, TM: Large Outflows Detected at ETF

Health Care Sector Update for 02/12/2016: GSK, NVS

These O'Shares ETFs Focus On Quality European Dividends

AveXis IPO: We Like This Goldman-Led Deal

Why Radius Health Inc. Dropped 45% in January

Good news from the clinical-stage osteoporosis specialist couldn't overcome January's biotech beat down.

Pre-Market Most Active for Feb 8, 2016 : CBX, NVS, TVIX, AZN, NOK, MT, BCRX, QQQ, FB, XIV, BAC, APO

Pre-Market Most Active for Feb 8, 2016 : CBX, NVS, TVIX, AZN, NOK, MT, BCRX, QQQ, FB, XIV, BAC, APOL

3 Potential Blockbusters Moving the Needle for Big Pharma in 2016

These pharmas have some recently approved drugs that could singlehandedly boost total sales this year.

See More NVS News...

NVS's Top Competitors

NVS $72.70 (0.69%)
Current stock: NVS
PFE $29.36 (0.79%)
Current stock: PFE
JNJ $101.82 (0.12%)
Current stock: JNJ
GSK $39.76 (1.56%)
Current stock: GSK